These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 29761426)

  • 1. Predictors of self-reported adherence to direct oral anticoagulation in a population of elderly men and women with non-valvular atrial fibrillation.
    Rossi AP; Facchinetti R; Ferrari E; Nori N; Sant S; Masciocchi E; Zoico E; Fantin F; Mazzali G; Zamboni M
    J Thromb Thrombolysis; 2018 Aug; 46(2):139-144. PubMed ID: 29761426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry.
    Sato T; Aizawa Y; Fuse K; Fujita S; Ikeda Y; Kitazawa H; Takahashi M; Okabe M
    J Stroke Cerebrovasc Dis; 2018 Nov; 27(11):3280-3288. PubMed ID: 30121155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.
    Borne RT; O'Donnell C; Turakhia MP; Varosy PD; Jackevicius CA; Marzec LN; Masoudi FA; Hess PL; Maddox TM; Ho PM
    BMC Cardiovasc Disord; 2017 Sep; 17(1):236. PubMed ID: 28865440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mixed methodology, non-interventional study to evaluate the use of direct oral anticoagulants in UK clinical practice for patients with a first stroke associated with non-valvular atrial fibrillation: study protocol.
    Bhat Y; Dixit A; Mistri A; Patel B; Quoraishi SH; Uprichard J
    BMC Neurol; 2019 Nov; 19(1):306. PubMed ID: 31783738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation.
    Oertel LB; Fogerty AE
    J Am Assoc Nurse Pract; 2017 Sep; 29(9):551-561. PubMed ID: 28805310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
    Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
    Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies.
    Deitelzweig S; Farmer C; Luo X; Vo L; Li X; Hamilton M; Horblyuk R; Ashaye A
    Curr Med Res Opin; 2017 Sep; 33(9):1583-1594. PubMed ID: 28644048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct oral anticoagulants use in elderly patients with non valvular atrial fibrillation: state of evidence.
    Benedetti G; Neccia M; Agati L
    Minerva Cardioangiol; 2018 Jun; 66(3):301-313. PubMed ID: 29125269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation.
    Okishige K; Nakamura T; Aoyagi H; Kawaguchi N; Yamashita M; Kurabayashi M; Suzuki H; Asano M; Shimura T; Yamauchi Y; Sasano T; Hirao K
    J Cardiol; 2017 Jan; 69(1):11-15. PubMed ID: 27160710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once- versus twice-daily direct oral anticoagulants in non-valvular atrial fibrillation.
    Ageno W; Beyer-Westendorf J; Rubboli A
    Expert Opin Pharmacother; 2017 Sep; 18(13):1325-1332. PubMed ID: 28786696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-reported adherence to anticoagulation and its determinants using the Morisky medication adherence scale.
    Castellucci LA; Shaw J; van der Salm K; Erkens P; Le Gal G; Petrcich W; Carrier M
    Thromb Res; 2015 Oct; 136(4):727-31. PubMed ID: 26272305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Horizontal vs. vertical dose reduction of direct oral anticoagulants in patients with non-valvular atrial fibrillation: definition and implications for practice.
    Rubboli A
    Eur J Intern Med; 2019 Apr; 62():e11-e12. PubMed ID: 30670343
    [No Abstract]   [Full Text] [Related]  

  • 13. Quality of direct oral anticoagulant prescribing in elderly patients with non-valvular atrial fibrillation: results from a large urban health system.
    Grant SJ; Kothari S; Gimotty PA; Gooneratne NS; Cuker A
    J Thromb Thrombolysis; 2018 Jul; 46(1):1-6. PubMed ID: 29611105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical characteristics of patients with atrial fibrillation treated with direct oral anticoagulants attended in primary care setting. The SILVER-AP study].
    de la Figuera M; Cinza S; Marín N; Egocheaga I; Prieto MA;
    Aten Primaria; 2018; 50(6):359-367. PubMed ID: 28764897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.
    Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Vo L
    Curr Med Res Opin; 2017 Sep; 33(9):1595-1604. PubMed ID: 28635338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medication adherence to direct anticoagulants in patients with non-valvular atrial fibrillation - A real world analysis.
    Brízido C; Ferreira AM; Lopes P; Strong C; Sá Mendes G; Fernandes Gama F; Durazzo A; Rocha Rodrigues G; Matos D; Guerreiro S; Madeira S; Ferreira J; Adragão P; Mendes M
    Rev Port Cardiol (Engl Ed); 2021 Sep; 40(9):669-675. PubMed ID: 34503705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of once- or twice-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with nonvalvular atrial fibrillation: A NOAC-TR study.
    Emren SV; Zoghi M; Berilgen R; Özdemir İH; Çelik O; Çetin N; Enhoş A; Köseoğlu C; Akyüz A; Doğan V; Levent F; Dereli Y; Doğan T; Başaran Ö; Karaca I; Karaca Ö; Otlu YÖ; Özmen Ç; Coşar S; Sümerkan M; Gürsul E; İnci S; Onrat E; Ergene O
    Bosn J Basic Med Sci; 2018 May; 18(2):185-190. PubMed ID: 28968197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015.
    Kjerpeseth LJ; Ellekjær H; Selmer R; Ariansen I; Furu K; Skovlund E
    Eur J Clin Pharmacol; 2017 Nov; 73(11):1417-1425. PubMed ID: 28735494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
    Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
    J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct oral anticoagulants: patient reported adherence and minor bleedings.
    Hayat A; Själander A; Wallvik J
    J Thromb Thrombolysis; 2023 Jul; 56(1):55-64. PubMed ID: 37119356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.